B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains a Neutral rating on ACADIA Pharmaceuticals (ACAD) and lowers the price target from $26 to $22.

May 10, 2024 | 11:48 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has maintained a Neutral rating on ACADIA Pharmaceuticals but reduced the price target from $26 to $22.
The reduction in price target by a reputable analyst firm like B of A Securities could lead to a negative short-term sentiment among investors, potentially causing a decrease in ACAD's stock price. The maintenance of a Neutral rating indicates that the firm does not see significant upside or downside from the current level, but the lowering of the price target suggests a reassessment of the stock's value, which could be perceived negatively by the market.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100